BRM424
Neurotrophic Keratitis
Phase 2Active (Orphan Drug Designation)
Key Facts
Indication
Neurotrophic Keratitis
Phase
Phase 2
Status
Active (Orphan Drug Designation)
Company
About BRIM Biotechnology
Taiwanese biotech developing regenerative peptide therapies for ophthalmology and osteoarthritis using its PDSP platform.
View full company profile